# A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury

> **NCT03229031** · PHASE3 · SUSPENDED · sponsor: **Eusol Biotech Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Spinal Cord Injuries

## Interventions

- **DRUG:** ES135

## Key facts

- **NCT ID:** NCT03229031
- **Lead sponsor:** Eusol Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2018-03-07
- **Primary completion:** 2024-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Why stopped:** low recruitment rate
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03229031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03229031, "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03229031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*